Filter Results
Clinical Studies
Results filtered:Study status:
Open
Contact Us for the Latest Status
Closed for Enrollment
Open
-
A Phase 2b/Phase 3, Randomized, Double-blind, Placebocontrolled, Multicenter Study, To Investigate The Efficacy And Safety Of Lunsekimig In Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized By An Eosinophilic Phenotype
Rochester, MN
This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype.
Participation to the study consists of 3 periods:
* Screening period of up to 4 weeks
* Randomized intervention period of approximately 48 weeks
* Follow-up period: Approximately 8 weeks The study duration will be up to 60 weeks.
-
Establishment of a digital platform for remote monitoring of COPD patients following bronchoscopic lung volume reduction
Rochester, MN
The purpose of this study is to determine if remote monitoring using the appropriate platform can improve the management of COPD patients after bronchoscopic lung volume reduction.
Contact Us for the Latest Status
-
An Open-label, Multicenter, Randomized, Non-Inferiority Pharmacokinetic And Safety/Tolerability Study Of Two Different Weekly Doses Of Alpha1- Proteinase Inhibitor Subcutaneous (Human) 15% In Patients With Alpha1-Antitrypsin Deficiency Compared To Corresponding Standard 60 Mg/kg/week And 120 Mg/kg/week Doses Of Intravenous Alpha1-Proteinase Inhibitor (5%)
Scottsdale/Phoenix, AZ
Rochester, MN
The purpose of this study is to demonstrate the safety and PK non-inferiority (via AUC0-7 days at steadystate) of Alpha-1 15% to Liquid Alpha1-PI in participants with AATD.
-
A Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose Expansion, And Single Repeat Dose Study Of TSRA-196 In Adults With The PiZZ Genotype Who Have Lung And/or Liver Disease Associated With Severe Alpha-1 Antitrypsin Deficiency
Jacksonville, FL
Rochester, MN
This is a Phase 1/2, open-label, multi-center, dose escalation (Part 1), dose expansion (Part 2), and single repeat dose (Part 3) study to evaluate the safety, tolerability, efficacy, and PK/PD parameters of TSRA-196 in adults with the PiZZ genotype who have lung and/or liver disease associated with severe alpha-1 antitrypsin deficiency (AATD)
-
A Phase 2b/Phase 3, Randomized, Double-blind, Placebocontrolled, Multicenter Study, To Investigate The Efficacy And Safety Of Lunsekimig In Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized By An Eosinophilic Phenotype
Jacksonville, FL
This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype.
Participation to the study consists of 3 periods:
* Screening period of up to 4 weeks
* Randomized intervention period of approximately 48 weeks
* Follow-up period: Approximately 8 weeks The study duration will be up to 60 weeks.
-
Establishment of a digital platform for remote monitoring of COPD patients following bronchoscopic lung volume reduction
Jacksonville, FL
The purpose of this study is to determine if remote monitoring using the appropriate platform can improve the management of COPD patients after bronchoscopic lung volume reduction.
Closed for Enrollment
-
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study To Evaluate The Long-term Efficacy And Safety Of Tozorakimab In Participants With Chronic Obstructive Pulmonary Disease (COPD) With A History Of Exacerbations (PROSPERO)
Rochester, MN
The purpose of this study is to evaluate the long-term effect of tozorakimab as an add on to standard of care (SoC) compared with SoC plus placebo on the time to first severe chronic obstructive pulmonary disease (COPD) exacerbation in former smokers.
-
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study To Assess The Efficacy, Safety And Tolerability Of Dupilumab In Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation
Rochester, MN
The primary purpose of this study is to evaluate the effectiveness of dupilumab administered every 2 weeks in patients with moderate-or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by - Annualized rate of acute moderate and severe COPD exacerbation (AECOPD).
-
Beta-Blocker Use in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Acute Myocardial Infarction (an Ancillary Study to Beta-Blockers for the Prevention of Acute Exacerbations of COPD) (BLOCK 2)
Rochester, MN
The purpose of this study is to determine the prevalence of COPD in patients admitted to the hospital with an acute myocardial infarction (AMI) and to characterize the phenotypic expression and severity of their underlying lung disease. Also to determine the association between beta-blocker use at discharge and cardiopulmonary outcomes in patients with COPD and AMI.
-
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home - a Multi-center Randomized Controlled Trial
Rochester, MN
The purpose of this study is to determine if myAirvo 3 use increases the time to first moderate exacerbation/severe exacerbation (hospitalization)/all-cause mortality in patients with moderate to very severe COPD. [ Time Frame: 1 year ]
.